CAS No. :	68767-14-6
Formula :	C₁₅H₁₈O₃
M.W :	246.30
SMILES Code :	CC(C1=CC=C(CC2C(CCC2)=O)C=C1)C(O)=O
Synonyms :	Koloxo; Loxoprofeno; Loxoprofene
MDL No. :	MFCD00864331
InChI Key :	YMBXTVYHTMGZDW-UHFFFAOYSA-N
Pubchem ID :	3965

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Human umbilical vein endothelial cells (HUVECs)	10 and 20 μg/mL	24 hours	Loxoprofen sodium suppressed endothelial AT2R elevation by angiotensin II, reduced ROS production, restored GSH levels, and inhibited NOX-2 and NOX-4 expression. Additionally, it improved mitochondrial membrane potential, enhanced cell viability, and reduced LDH release. Importantly, loxoprofen protected endothelial cells from apoptosis by balancing the expression of Bax, Bcl-2, and caspase-3.	Drug Des Devel Ther. 2020 Nov 18;14:5087-5096
Raw264.7 cells	100 µg/mL	24 hours	Evaluate the anti-inflammatory effects of different formulations on Raw264.7 cells, results showed that the combination of Lox and Tof significantly downregulated the expression of inflammatory cytokines IL-1β and iNOS	Pharmaceutics. 2023 May 15;15(5):1500
dog liver microsomes	5 µM	60 minutes	Studied the metabolism of loxoprofen in dog liver microsomes, showing higher glucuronidation activity compared to other species.	Pharmaceutics. 2018 Aug 2;10(3):112
mouse liver microsomes	5 µM	60 minutes	Studied the metabolism of loxoprofen in mouse liver microsomes, showing higher Phase I metabolic activity compared to other species.	Pharmaceutics. 2018 Aug 2;10(3):112
human liver microsomes	5 µM	60 minutes	Investigated the metabolic stability of loxoprofen in human liver microsomes, showing a marked decrease in stability and production of various metabolites.	Pharmaceutics. 2018 Aug 2;10(3):112

SD rats	Carrageenan/kaolin-induced arthritis model	Transdermal delivery (microneedle patch)	494.99 ± 6.15 µg/patch (Lox), 36.84 ± 4.14 µg/patch (Tof)	Single administration, observation for 7 days	Evaluate the therapeutic efficacy of Lox + Tof NPs@MN on arthritis, results showed that the formulation significantly reduced joint swelling, muscle atrophy, and cartilage destruction, and downregulated the mRNA expression of inflammatory cytokines TNF-α, IL-1β, iNOS, JAK2, JAK3, and STAT3	Pharmaceutics. 2023 May 15;15(5):1500
ICR mice	Mouse model treated with CYP3A modulators	Oral	20 mg/kg	Single dose	To investigate the effects of DEX and KTC pretreatment on the pharmacokinetic parameters of loxoprofen and its metabolites, it was found that DEX significantly decreased the concentration of active metabolites, while KTC increased the concentration of active metabolites.	Pharmaceutics. 2019 Sep 16;11(9):479
Beagle dogs	Fasted beagle dogs	Oral	90 mg	Single dose, lasting 12 hours	To evaluate the pharmacokinetic properties of the optimal sustained-release pellets, which showed a more stable and prolonged plasma drug concentration profile compared to the immediate-release tablets, with a relative bioavailability of 87.16%.	Pharmaceutics. 2019 Jun 5;11(6):260
Mice	BLT2-deficient mice	Oral administration in drinking water	30 μg/mL	7 days	Pretreatment with loxoprofen increased mortality after PLY administration	Sci Rep. 2016 Oct 5;6:34560

NCT02384928	Sciatica Inte... More >>rvertebral Disc Displacement Less <<	Not Applicable	Completed	-	Korea, Republic of ... More >> Jaseng Hospital of Korean Medicine Seoul, Gangnam-Gu, Korea, Republic of, 135-896 Less <<
NCT03386149	Lumbar Disc Herniation	Phase 3	Recruiting	September 30, 2018	Korea, Republic of ... More >> Dongguk University Bundang Oriental Hospital Recruiting Seongnam, Gyeonggi, Korea, Republic of, 13601 Contact: Eun-Jung Kim, PhD., KMD +82317103751 hanijjung@naver.com Daegu Korean Medicine Hospital of Daegu Haany University Recruiting Daegu, Korea, Republic of, 42158 Contact: I-Rang Choi, B.S +82537702324 soongood88@dhu.ac.kr Kyunghee University Medical Center Recruiting Seoul, Korea, Republic of, 02447 Contact: Sae-Rom Jeon, B.S. +821050478756 sr9213@naver.com Kyung Hee University Hospital at Gangdong Recruiting Seoul, Korea, Republic of, 05278 Contact: Bonhyuk Goo, M.S., KMD +8224406099 goobh99@naver.com Less <<
NCT02467504	Rheumatoid Arthritis	Phase 2	Unknown	June 2017	China, Beijing ... More >> Department of Rheumatology and Immunology, Peking University People's Hospital Recruiting Beijing, Beijing, China, 100044 Contact: Xiaoying Zhang, MD +8613810001444 xiaoying19880307@163.com Less <<
NCT01922466	Chronic Non-specific, Uncompli... More >>cated Neck Pain Less <<	Phase 2	Completed	-	Korea, Republic of ... More >> Spine Center, Kyung Hee University Hospital at Gangdong Seoul, Korea, Republic of, 134-727 Less <<
NCT02983747	Low Back Pain	Not Applicable	Active, not recruiting	December 2019	China ... More >> Shanghai Changzheng Hospital Shanghai, China, 200003 Less <<
NCT02831569	Pain	Phase 3	Completed	-	Japan ... More >> Fukuwa Clinic Tokyo, Chuo-ku, Japan, 103-0027 Tokyo-Eki Center-building Clinic Tokyo, Chuo-ku, Japan, 103-0027 Shinjuku Res. Park Clinic, Tokyo, I.M. Tokyo, Shinjyuku-ku, Japan, 169-0073 Less <<
NCT02602353	Delayed Onset Muscle Soreness	Phase 2	Completed	-	United States, Utah ... More >> Jean Brown Research Salt Lake City, Utah, United States, 84124 Less <<
NCT00994461	Healthy Volunteers	Phase 4	Completed	-	Japan ... More >> Pfizer Investigational Site Yokohama, Kanagawa, Japan Pfizer Investigational Site Minato-ku, Tokyo, Japan Pfizer Investigational Site Shinjuku-ku, Tokyo, Japan Less <<
NCT01491321	Chronic Low Back Pain	Phase 2	Unknown	March 2012	Korea, Republic of ... More >> Spine Center, Kyung Hee University Hospital at Gangdong Recruiting Seoul, Korea, Republic of, 134-727 Contact: Byung-Kwan Seo seohbk@hanmail.net Contact: Yoon-Su Park 82-2-440-7482 Less <<
NCT01779271	Acute Upper Respiratory Infect... More >>ion Fever Less <<	Phase 3	Completed	-	Korea, Republic of ... More >> Chung-Ang University Hospital, South Korea Seoul, Korea, Republic of Less <<
NCT00141154	Low Back Pain	Phase 3	Completed	-	Japan ... More >> Pfizer Investigational Site Funabashi-shi, Chiba, Japan Pfizer Investigational Site Funabashi, Chiba, Japan, 273-0035 Pfizer Investigational Site Matsudo-shi, Chiba, Japan Pfizer Investigational Site Fukuoka-shi, Fukuoka, Japan Pfizer Investigational Site Chitose, Hokkaido, Japan, 066-0026 Pfizer Investigational Site Sapporo-shi, Hokkaido, Japan Pfizer Investigational Site Sapporo, Hokkaido, Japan Pfizer Investigational Site Katougun, Hyogo, Japan, 673-1462 Pfizer Investigational Site Kobe, Hyogo, Japan, 650 0004 Pfizer Investigational Site Nishinomiya, Hyogo, Japan, 662-0838 Pfizer Investigational Site Sagamihara-shi, Kanagawa, Japan Pfizer Investigational Site Yokohama-shi, Kanagawa, Japan Pfizer Investigational Site Yokohama, Kanagawa, Japan Pfizer Investigational Site Hatogaya-shi, Saitama, Japan Pfizer Investigational Site Kumagaya-shi, Saitama, Japan, 3600012 Pfizer Investigational Site Kumagayashi, Saitama, Japan, 3600854 Pfizer Investigational Site Minamisaitama-gun, Saitama, Japan Pfizer Investigational Site Saitama-shi, Saitama, Japan Pfizer Investigational Site Tokorozawa, Saitama, Japan Pfizer Investigational Site Adachi-Ku, Tokyo, Japan Pfizer Investigational Site Bunkyou-ku, Tokyo, Japan Pfizer Investigational Site Edogawa-ku, Tokyo, Japan Pfizer Investigational Site Itabashi-ku, Tokyo, Japan Pfizer Investigational Site Koito-ku, Tokyo, Japan Pfizer Investigational Site Meguro-Ku, Tokyo, Japan Pfizer Investigational Site Nakano-ku, Tokyo, Japan Pfizer Investigational Site Nerima-ku, Tokyo, Japan Pfizer Investigational Site Ota-Ku, Tokyo, Japan, 145-0066 Pfizer Investigational Site Ota-Ku, Tokyo, Japan Pfizer Investigational Site Setagaya-ku, Tokyo, Japan Pfizer Investigational Site Shibuya-ku, Tokyo, Japan Pfizer Investigational Site Shinagawa-ku, Tokyo, Japan, 140-0001 Pfizer Investigational Site Shinjyuku-ku, Tokyo, Japan Pfizer Investigational Site Suginami-ku, Tokyo, Japan Pfizer Investigational Site Sumida-ku, Tokyo, Japan, 131-0043 Pfizer Investigational Site Toyoshima-ku, Tokyo, Japan Pfizer Investigational Site Chiba, Japan, 266-0031 Pfizer Investigational Site Fukuoka, Japan, 810-0004 Pfizer Investigational Site Fukuoka, Japan Pfizer Investigational Site Tokyo, Japan, 140-0011 Less <<
NCT02831569	-		Completed	-	-
NCT02616068	Trauma Pain	Phase 3	Completed	-	Brazil ... More >> Ctd Clinica de Terapia Da Dor Ltda Salvador, Bahia, Brazil, 40170-150 Med Centro de Estudos- Crd- Centro Goiania, Goias, Brazil, 74020-010 CMiP - Centro Mineiro de Pesquisa Juiz de Fora, Minas Gerais, Brazil, 36010-570 Hospital São Vicente de Paulo Passo Fundo, Rio Grande do Sul, Brazil, 99010-080 HMCG - Hospital e Maternidade Dr. Christovão da Gama Santo Andre, Sao Paulo, Brazil, 09030-010 Faculdade de Medicina do ABC Santo André, Sao Paulo, Brazil, 09060-650 Fundação Faculdade Regional de Medicina de São José do Rio Preto São José do Rio Preto, Sao Paulo, Brazil, 15090-000 Hospital Nipo-Brasileiro São Paulo, Brazil, 02189-010 Less <<
NCT00676117	Healthy	Phase 1	Completed	-	Japan ... More >> Research Site Osaka-city, Osaka, Japan Less <<
NCT00994461	-		Completed	-	-

{[proInfo.proName]}

CAS No.: 68767-14-6

{[proInfo.proName]}

CAS No.: 68767-14-6

Alternative Products

Product Details of Loxoprofen

Safety of Loxoprofen

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	4.06mL 0.81mL 0.41mL	20.30mL 4.06mL 2.03mL	40.60mL 8.12mL 4.06mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed